Literature DB >> 18043098

Is there still a role for total pancreatectomy?

Michael W Müller1, Helmut Friess, Jörg Kleeff, Rolf Dahmen, Markus Wagner, Ulf Hinz, Daniela Breisch-Girbig, Güralp O Ceyhan, Markus W Büchler.   

Abstract

OBJECTIVE: To evaluate the perioperative and long-term results of total pancreatectomy (TP), and to assess whether it provides morbidity, mortality, and quality of life (QoL) comparable to those of the pylorus-preserving (pp)-Whipple procedure in patients with benign and malignant pancreatic disease. SUMMARY BACKGROUND DATA: TP was abandoned for decades because of high peri- and postoperative morbidity and mortality. Because selected pancreatic diseases are best treated by TP, and pancreatic surgery and postoperative management of exocrine and endocrine insufficiency have significantly improved, the hesitance to perform a TP is disappearing. PATIENTS AND METHODS: In a prospective study conducted from October 2001 to November 2006, all patients undergoing a TP (n = 147; 100 primary elective TP [group A], 24 elective TP after previous pancreatic resection [group B], and 23 completion pancreatectomies for complications) were included, and perioperative and late follow-up data, including the QoL (EORTC QLQ-C30 questionnaire), were evaluated. A matched-pairs analysis with patients receiving a pp-Whipple operation was performed.
RESULTS: Indications for an elective TP (group A + B) were pancreatic and periampullary adenocarcinoma (n = 71), other neoplastic pancreatic tumors (intraductal papillary mucinous neoplasms, neuroendocrine tumors, cystic tumors; n = 34), metastatic lesions (n = 8), and chronic pancreatitis (n = 11). There were 73 men and 51 women with a mean age of 60.9 +/- 11.3 years. Median intraoperative blood loss was 1000 mL and median operation time was 380 minutes. Postoperative surgical morbidity was 24%, medical morbidity was 15%, and mortality was 4.8%. The relaparotomy rate was 12%. Median postoperative hospital stay was 11 days. After a median follow-up of 23 months, global health status of TP patients was comparable to that of pp-Whipple patients, although a few single QoL items were reduced. All patients required insulin and exocrine pancreatic enzyme replacements. The mean HbA1c value was 7.3% +/- 0.9%.
CONCLUSION: In this cohort study, mortality and morbidity rates after elective TP are not significantly different from the pp-Whipple. Because of improvements in postoperative management, QoL is acceptable, and is almost comparable to that of pp-Whipple patients. Therefore, TP should no longer be generally avoided, because it is a viable option in selected patients.

Entities:  

Mesh:

Year:  2007        PMID: 18043098     DOI: 10.1097/SLA.0b013e31815c2ca3

Source DB:  PubMed          Journal:  Ann Surg        ISSN: 0003-4932            Impact factor:   12.969


  78 in total

1.  Pancreatic cancer arising from the remnant pancreas after pancreatectomy: a multicenter retrospective study by the Kyushu Study Group of Clinical Cancer.

Authors:  Daisuke Hashimoto; Kota Arima; Shigeki Nakagawa; Yuji Negoro; Toshihiko Hirata; Masahiko Hirota; Masafumi Inomata; Kengo Fukuzawa; Takefumi Ohga; Hiroshi Saeki; Eiji Oki; Yo-Ichi Yamashita; Akira Chikamoto; Hideo Baba; Yoshihiko Maehara
Journal:  J Gastroenterol       Date:  2018-12-04       Impact factor: 7.527

Review 2.  Pancreatic surgery: evolution and current tailored approach.

Authors:  Mario Zovak; Dubravka Mužina Mišić; Goran Glavčić
Journal:  Hepatobiliary Surg Nutr       Date:  2014-10       Impact factor: 7.293

3.  Total pancreatectomy with islet autotransplantation: an overview.

Authors:  Seok L Ong; Gianpiero Gravante; Cristina A Pollard; M'balu A Webb; Severine Illouz; Ashley R Dennison
Journal:  HPB (Oxford)       Date:  2009-12       Impact factor: 3.647

4.  Total pancreatectomy for pancreatic cancer: indications and operative technique.

Authors:  Yakup Kulu; Bruno M Schmied; Jens Werner; Pietro Muselli; Markus W Büchler; Jan Schmidt
Journal:  HPB (Oxford)       Date:  2009-09       Impact factor: 3.647

5.  Reconstruction of the common hepatic artery at the time of total pancreatectomy using a splenohepatic bypass.

Authors:  Matthias H Seelig; Orlin Belyaev; Waldemar Uhl
Journal:  J Gastrointest Surg       Date:  2010-02-09       Impact factor: 3.452

Review 6.  Perioperative management of endocrine insufficiency after total pancreatectomy for neoplasia.

Authors:  Ajay V Maker; Raashid Sheikh; Vinita Bhagia
Journal:  Langenbecks Arch Surg       Date:  2017-07-21       Impact factor: 3.445

7.  [Total pancreatectomy: renaissance of a surgical procedure].

Authors:  T Keck; U T Hopt
Journal:  Chirurg       Date:  2008-12       Impact factor: 0.955

8.  Impact of total pancreatectomy: short- and long-term assessment.

Authors:  Louise Barbier; Wisam Jamal; Safi Dokmak; Béatrice Aussilhou; Olivier Corcos; Philippe Ruszniewski; Jacques Belghiti; Alain Sauvanet
Journal:  HPB (Oxford)       Date:  2013-01-29       Impact factor: 3.647

9.  Indications and early outcomes for total pancreatectomy at a high-volume pancreas center.

Authors:  Monika S Janot; Orlin Belyaev; Sabine Kersting; Ansgar M Chromik; Matthias H Seelig; Dominique Sülberg; Ulrich Mittelkötter; Waldemar H Uhl
Journal:  HPB Surg       Date:  2010-06-23

Review 10.  Perioperative management in distal pancreatectomy: results of a survey in 23 European participating centres of the DISPACT trial and a review of literature.

Authors:  Helge Bruns; Nuh N Rahbari; Thorsten Löffler; Markus K Diener; Christoph M Seiler; Matthias Glanemann; Giovanni Butturini; Christoph Schuhmacher; Inga Rossion; Markus W Büchler; Tido Junghans
Journal:  Trials       Date:  2009-07-26       Impact factor: 2.279

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.